IP Library Granted Patent US 9,066,917
Granted Patent B2
US 9,066,917 · App. 14/224,040 · Granted Jun 30, 2015

Mixed metal compound

Inventors: Richard Jonathan Applewhite (Cheshire, GB); James David Morrison (Norwich, GB); Maurice Sydney Newton (Sandbacj, GB); Nigel Peter Rhodes (Warrington, GB); Christopher John Rickard (Sandiway Northwich, GB)
Assignee: CYTOCHROMA DEVELOPMENT INC.
A61K33/26A61K6/04A61K9/143A61K9/1611A61K9/1682A61K33/06A61K33/10A61K45/06B82Y30/00C01G49/009C01P2002/22C01P2002/72C01P2004/61C01P2004/64C01P2006/11C01P2006/12C01P2006/14C01P2006/80C01P2006/82
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,066,917
App. No.
14/224,040
Granted
Jun 30, 2015
Kind
B2
Abstract

There is provided a method of producing a mixed metal compound comprising at least Mg 2+ and at least Fe 3+ having an aluminum content of less than 10000 ppm, having an average crystal size of less than 20 nm (200 A) comprising the steps of: (a) combining a Mg 2+ salt and a Fe 3+ salt with Na 2 CO 3 and NaOH to produce a slurry, wherein the pH of the slurry is maintained at from 9 5 to 1 1, and wherein the Na 2 CO 3 is provided at an excess of 0 to 4.0 moles than is required to complete the reaction (b) subjecting the slurry to mixing under conditions providing a power per unit volume of 0 03 to 1.6 kW/m 3 (c) separating the mixed metal compound from the slurry, to obtain a crude product having a dry solid content of at least 10 wt % (d) drying the crude product either by (i) heating the crude product to a temperature of no greater than 150° C. and sufficient to provide a water evaporation rate of 0.05 to 1 5 kg water per hour per kg of dry product, or (H) exposing the crude product to rapid drying at a water evaporation rate of 500 to 50000 kg water per hour per kg of dry product.

Claims (92)

1. A mixed metal compound comprising at least Mg 2+ and at least Fe 3+ ,

wherein

the molar ratio of Mg 2+ to Fe 3+ is 2.5:1 to 1.5:1,

the mixed metal compound has an aluminium content of less than 10000 ppm,

the average crystal size of the mixed metal compound is from 10 to 20 nm (100 to 200 Å),

and the d50 average particle size of the mixed metal compound is less than 300 μm.

2. A mixed metal compound according to claim 1 wherein the d50 average particle size of the mixed metal compound is less than 200 μm.

3. A mixed metal compound comprising at least Mg 2+ and at least Fe 3+ ,

wherein

the molar ratio of Mg 2+ to Fe 3+ is 2.5:1 to 1.5:1,

the mixed metal compound has an aluminium content of less than 10000 ppm,

the average crystal size of the mixed metal compound is from 10 to 20 nm (100 to 200 Å),

and the water pore volume of the mixed metal compound is from 0.25 to 0.7 cm 3 /g of mixed metal compound.

4. A mixed metal compound according to claim 3 wherein water pore volume of the mixed metal compound is from 0.3 to 0.65 cm 3 /g of mixed metal compound.

5. A mixed metal compound according to claim 3 wherein the nitrogen pore volume of the mixed metal compound is from 0.28 to 0.56 cm 3 /g.

6. A mixed metal compound comprising at least Mg 2+ and at least Fe 3+ ,

wherein

the molar ratio of Mg 2+ to Fe 3+ is 2.5:1 to 1.5:1,

the mixed metal compound has an aluminium content of less than 10000 ppm, and

(a)(i) the average crystal size of the mixed metal compound is from 10 to 20 nm (100 to 200 Å)

and (a)(ii) the interlayer sulphate content of the compound is from 2 to 5 wt %; or

(b)(i) the average crystal size of the mixed metal compound is less than 20 nm (200 Å) and (b)(ii) the interlayer sulphate content of the compound is from 2.1 to 5 wt %.

7. A mixed metal compound according to claim 6 wherein the average crystal size of the mixed metal compound is from 12 to 20 nm (120 to 200 Å).

8. A mixed metal compound comprising at least Mg 2+ and at least Fe 3+ ,

wherein

the molar ratio of Mg 2+ to Fe 3+ is 2.5:1 to 1.5:1,

the mixed metal compound has an aluminium content of less than 10000 ppm, and

(a)(i) the average crystal size of the mixed metal compound is less than 20 nm (200 Å) and (a)(ii) the surface area is from 80 to 145 m 2 per gram of compound

or

(b)(i) the average crystal size of the mixed metal compound is from 10 to 20 nm (100 to 200 Å)

and (b)(ii) the surface area is from 40 to 80 m 2 per gram of compound.

9. A mixed metal compound according to claim 8 wherein the compound has a d50 average particle size of from 10 to 350 μm.

10. A mixed metal compound according to claim 8 wherein the compound has a d50 average particle size of from 10 to 100 μm.

11. A mixed metal compound according to claim 8 wherein the compound releases magnesium in an amount less than 0.15 mmol magnesium/g compound, when the compound is mixed with 40 mM phosphate buffer solution (pH 4) at 37.5° C. and shook for 30 minutes.

12. A mixed metal compound according to claim 8 wherein the water pore volume of the mixed metal compound is from 0.25 to 0.7 cm 3 /g of mixed metal compound.

13. A compound according to claim 1 wherein the compound is of the formula

M II 1-x M III x (OH) 2 A n− y .m H 2 O

wherein M III is one or more bivalent metals and is at least Mg 2+ ;

M III is one or more trivalent metals and is at least Fe 3+ ;

A n− is one or more n-valent anions and is at least CO 3 2− ;

x/Σyn is from 1 to 1.2

0<x≦0.4,

0<y≦1 and

0<m≦10.

14. A compound according to claim 13 wherein x/Σyn is from 1.05 to 1.15.

15. A compound according to claim 13 wherein x/Σyn is 1.

16. A compound according to claim 1 wherein the compound has an aluminium content of less than 30 ppm.

17. A compound according to claim 1 wherein the interlayer sulphate content of the compound is from 2 to 5 wt %.

18. A compound according to claim 1 wherein the compound has a d50 average particle size of less than 100 μm.

19. A compound according to claim 1 wherein the compound has a d50 average particle size of 5 to 50 μm.

20. A compound according to claim 1 wherein the compound has a d50 average particle size of approximately 5 μm.

21. A compound according to claim 1 wherein the water pore volume of the mixed metal compound is from 0.25 to 0.7 cm 3 /g of mixed metal compound.

22. A compound according to claim 1 wherein the compound has a dry solid content of at least 20 wt %.

23. A compound according to claim 3 wherein the compound is of the formula

M II 1-x M III x (OH) 2 A n− y .m H 2 O

wherein M II is one or more bivalent metals and is at least Mg 2+ ;

M III is one or more trivalent metals and is at least Fe 3+ ;

A n− is one or more n-valent anions and is at least CO 3 2− ;

x/Σyn is from 1 to 1.2

0<x≦0.4,

0<y≦1 and

0<m≦10.

24. A compound according to claim 6 wherein the compound is of the formula

M II 1-x M III x (OH) 2 A n− y .m H 2 O

wherein M II is one or more bivalent metals and is at least Mg 2+ ;

M III is one or more trivalent metals and is at least Fe 3+ ;

A n− is one or more n-valent anions and is at least CO 3 2− ;

x/Σyn is from 1 to 1.2

0<x≦0.4,

0<y≦1 and

0<m≦10.

25. A compound according to claim 8 wherein the compound is of the formula

M II 1-x M III x (OH) 2 A n− y .m H 2 O

wherein M II is one or more bivalent metals and is at least Mg 2+ ;

M III is one or more trivalent metals and is at least Fe 3+ ;

A n− is one or more n-valent anions and is at least CO 3 2− ;

x/Σyn is from 1 to 1.2

0<x≦0.4,

0<y≦1 and

0<m≦10.

26. A compound according to claim 3 wherein the compound has a dry solid content of at least 20 wt %.

27. A compound according to claim 6 wherein the compound has a dry solid content of at least 20 wt %.

28. A compound according to claim 8 wherein the compound has a dry solid content of at least 20 wt %.

29. A compound according to claim 6 wherein the water pore volume of the mixed metal compound is from 0.25 to 0.7 cm 3 /g of mixed metal compound.

30. A pharmaceutical composition comprising a mixed metal compound as defined in claim 1 and optionally one or more pharmaceutically acceptable adjuvants, excipients, diluents or carriers.

31. A pharmaceutical composition according to claim 30 in the form of a tablet, capsule or granule.

32. A pharmaceutical composition comprising a mixed metal compound as defined in claim 3 and optionally one or more pharmaceutically acceptable adjuvants, excipients, diluents or carriers.

33. A pharmaceutical composition according to claim 32 in the form of a tablet, capsule or granule.

34. A pharmaceutical composition comprising a mixed metal compound as defined in claim 6 and optionally one or more pharmaceutically acceptable adjuvants, excipients, diluents or carriers.

35. A pharmaceutical composition according to claim 34 in the form of a tablet, capsule or granule.

36. A pharmaceutical composition comprising a mixed metal compound as defined in claim 8 and optionally one or more pharmaceutically acceptable adjuvants, excipients, diluents or carriers.

37. A pharmaceutical composition according to claim 36 in the form of a tablet, capsule or granule.

Assignments (9)
CONFIRMATORY ASSIGNMENT Recorded May 6, 2021
From: OPKO IRELAND GLOBAL HOLDINGS, LTD.
To: EIRGEN PHARMA LTD.
Reel/Frame 056167/0196 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2015
From: APPLEWHITE, RICHARD JONATHAN; MORRISON, JAMES DAVID; NEWTON, MAURICE SYDNEY; RHODES, NIGEL PETER; RICKARD, CHRISTOPHER JOHN
To: INEOS HEALTHCARE LIMITED
Reel/Frame 036210/0091 →
NUNC PRO TUNC ASSIGNMENT Recorded Jul 29, 2015
From: INEOS HEALTHCARE LIMITED
To: CYTOCHROMA DEVELOPMENT INC.
Reel/Frame 036210/0165 →
CONFIRMATORY PATENT RIGHTS AGREEMENT Recorded Jul 29, 2015
From: CYTOCHROMA DEVELOPMENT INC.
To: CYTOCHROMA CAYMAN ISLANDS, LTD.
Reel/Frame 036214/0582 →
CONFIRMATORY PATENT RIGHTS AGREEMENT Recorded Jul 29, 2015
From: CYTOCHROMA CAYMAN ISLANDS, LTD.
To: OPKO IP HOLDINGS, INC.
Reel/Frame 036216/0056 →
CONFIRMATORY PATENT RIGHTS AGREEMENT Recorded Jul 29, 2015
From: OPKO IP HOLDINGS, INC.
To: OPKO HOLDINGS, INC.
Reel/Frame 036216/0224 →
CONFIRMATORY PATENT RIGHTS AGREEMENT Recorded Jul 29, 2015
From: OPKO HOLDINGS, INC.
To: OPKO IRELAND GLOBAL HOLDINGS, LTD.
Reel/Frame 036227/0134 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2014
From: APPLEWHITE, RICHARD JONATHAN; MORRISON, JAMES DAVID; NEWTON, MAURICE SYDNEY; RHODES, NIGEL PETER; RICKARD, CHRISTOPHER JOHN
To: INEOS HEALTHCARE LIMITED
Reel/Frame 033505/0891 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2014
From: INEOS HEALTHCARE LIMITED
To: CYTOCHROMA DEVELOPMENT INC.
Reel/Frame 033506/0233 →
Priority Claims (1)
GB 913525.2 · Aug 3, 2009 · national
Continuity (2)
Division 13388476
Related Publication 20140205667A1 · Jul 24, 2014